Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?

키워드

참고문헌 (102)

1. "Global tuberculosis report 2014" (2015)[URL]
2. Glaziou P, "Global epidemiology of tuberculosis", Semin Respir Crit Care Med, 34, pp.3~16 (2013)
3. Chang KC, "Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012", Respirology, 18, pp.8~21 (2013)
4. Falzon D, "Multidrug-resistant tuberculosis around the world: what progress has been made?", Eur Respir J, 45, pp.150~160 (2015)
5. Udwadia ZF, "Totally drug-resistant tuberculosis in India", Clin Infect Dis, 54, pp.579~581 (2012)
6. Klopper M, "Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa", Emerg Infect Dis, 19, pp.449~455 (2013)
7. Dheda K, "Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis", Lancet Respir Med, 2, pp.321~338 (2014)
8. Fox W, "Short-course chemotherapy for tuberculosis", Lancet, 2, pp.1349~1350 (1976)
9. Mitchison D, "The chemotherapy of tuberculosis:past, present and future", Int J Tuberc Lung Dis, 16, pp.724~732 (2012)
10. Zhang Y, "Targeting persisters for tuberculosis control", Antimicrob Agents Chemother, 56, pp.2223~2230 (2012)
11. "Treatment of tuberculosis:guidelines for national programmes (4th edition)" (2015)[URL]
12. Yew WW, "Emerging drugs for the treatment of tuberculosis", Expert Opin Emerg Drugs, 16, pp.1~21 (2011)
13. Zumla AI, "New antituberculosis drugs, regimens, and adjunct therapies:needs, advances, and future prospects", Lancet Infect Dis, 14, pp.327~340 (2014)
14. Sirgel FA, "The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis", Am J Respir Crit Care Med, 172, pp.128~135 (2005)
15. Mitchison DA, "The action of antituberculosis drugs in short-course chemotherapy", Tubercle, 66, pp.219~225 (1985)
16. Mitchison DA, "The diagnosis and therapy of tuberculosis during the past 100 years", Am J Respir Crit Care Med, 171, pp.699~706 (2005)
17. Dorman SE, "Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium", J Infect Dis, 206, pp.1030~1040 (2012)
18. Dorman SE, "Daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial", Am J Respir Crit Care Med, 191, pp.333~343 (2015)
19. Boeree MJ, "A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis", Am J Respir Crit Care Med, 191, pp.1058~1065 (2015)
20. Satyaraddi A, "Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity", Int J Tuberc Lung Dis, 18, pp.188~195 (2014)
21. Horne DJ, "Sputum monitoring during tuberculosis treatment for predicting outcome : systematic review and meta-analysis", Lancet Infect Dis, 10, pp.387~394 (2010)
22. Mukamolova GV, "Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum", Am J Respir Crit Care Med, 181, pp.174~180 (2010)
23. De Groote MA, "Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment", PLoS One, 8, pp.e61002~ (2013)
24. Garton NJ, "Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum", PLoS Med, 5, pp.e75~ (2008)
25. Nikolayevskyy V, "Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease", Tuberculosis, 95, pp.179~185 (2015)
26. Nuermberger EL, "Moxif loxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis", Am J Respir Crit Care Med, 169, pp.421~426 (2004)
27. Nuermberger EL, "Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis", Am J Respir Crit Care Med, 170, pp.1131~1134 (2004)
28. Burman WJ, "Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis", Am J Respir Crit Care Med, 174, pp.331~338 (2006)
29. Dorman SE, "Substitution of moxif loxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis", Am J Respir Crit Care Med, 180, pp.273~280 (2009)
30. Wang JY, "Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis", Int J Tuberc Lung Dis, 14, pp.65~71 (2010)
31. Conde MB, "Moxifloxacin versus ethambutol in the initial treatment of tuberculosis:a double-blind, randomised, controlled phase II trial", Lancet, 373, pp.1183~1189 (2009)
32. Jawahar MS, "Randomized clinical trial of thrice-weekly 4-month moxif loxacin or gatif loxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients", PLoS One, 8, pp.e67030~ (2013)
33. Gillespie SH, "Fourmonth moxifloxacin-based regimens for drug-sensitive tuberculosis", N Engl J Med, 371, pp.1577~1587 (2014)
34. Merle CS, "A four-month gatifloxacin-containing regimen for treating tuberculosis", N Engl J Med, 371, pp.1588~1598 (2014)
35. Jindani A, "High-dose rifapentine with moxifloxacin for pulmonary tuberculosis", N Engl J Med, 371, pp.1599~1608 (2014)
36. Velayutham BV, "Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India", Clin Infect Dis, 59, pp.e142~e149 (2014)
37. Rustomjee R, "Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis", Antimicrob Agents Chemother, 52, pp.2831~2835 (2008)
38. Diacon AH, "Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline", Am J Respir Crit Care Med, 191, pp.943~953 (2015)
39. Diacon AH, "Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients", Int J Tuberc Lung Dis, 15, pp.949~954 (2011)
40. Diacon AH, "Early bactericidal activity and pharmacokinetics of PA-824in smear-positive tuberculosis patients", Antimicrob Agents Chemother, 54, pp.3402~3407 (2010)
41. Diacon AH, "Phase II dose-ranging trial of the early bactericidal activity of PA-824", Antimicrob Agents Chemother, 56, pp.3027~3031 (2012)
42. Diacon AH, "14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxif loxacin combinations: a randomised trial", Lancet, 380, pp.986~993 (2012)
43. Dawson R, "Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis", Lancet, 385, pp.1738~1747 (2015)
44. Wallis RS, "Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA)and blood (WBA) of patients with pulmonary tuberculosis", PLoS One, 9, pp.e94462~ (2014)
45. Olaru ID, "Novel drugs against tuberculosis: a clinician’s perspective", Eur Respir J, 45, pp.1119~1131 (2015)
46. Jindani A, "Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days", Am J Respir Crit Care Med, 167, pp.1348~1354 (2003)
47. Gunther G, "Multidrug-resistant tuberculosis in Europe, 2010-2011", Emerg Infect Dis, 21, pp.409~416 (2015)
48. Nijland HM, "Rifampicin reduces plasma concentrations of moxif loxacin in patients with tuberculosis", Clin Infect Dis, 45, pp.1001~1007 (2007)
49. Heinrich N, "Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients", J Antimicrob Chemother, 70, pp.1558~1566 (2015)
50. Svensson EM, "Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug", J Antimicrob Chemother, 70, pp.1106~1114 (2015)
51. Yew WW, "Clinically significant interactions with drugs used in the treatment of tuberculosis", Drug Saf, 25, pp.111~133 (2002)
52. Dooley KE, "Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267", J Acquir Immune Defic Syndr, 59, pp.455~462 (2012)
53. Svensson EM, "Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis", Antimicrob Agents Chemother, 57, pp.2780~2787 (2013)
54. Svensson EM, "Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection", Antimicrob Agents Chemother, 58, pp.6406~6412 (2014)
55. Dooley KE, "TB and HIV therapeutics: pharmacology research priorities", AIDS Res Treat, 2012, pp.874083~ (2012)
56. Dooley KE, "Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin", Antimicrob Agents Chemother, 58, pp.5245~5252 (2014)
57. Shimokawa Y, "Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro", Biol Pharm Bull, 37, pp.1727~1735 (2014)
58. Jia L, "Interspecies pharmacokinetics and in vitro metabolism of SQ109", Br J Pharmacol, 147, pp.476~485 (2006)
59. Reddy VM, "In vitro interactions between new antitubercular drug candidates SQ109 and TMC207", Antimicrob Agents Chemother, 54, pp.2840~2846 (2010)
60. Ahuja SD, "Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients", PLoS Med, 9, pp.e1001300~ (2012)
61. Mdluli K, "The tuberculosis drug discovery and development pipeline and emerging drug targets", Cold Spring Harb Perspect Med, 5, pp.a021154~ (2015)
62. Falzon D, "WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update", Eur Respir J, 38, pp.516~528 (2011)
63. Van Deun A, "Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis", Am J Respir Crit Care Med, 182, pp.684~692 (2010)
64. Grosset JH, "Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice", Am J Respir Crit Care Med, 188, pp.608~612 (2013)
65. Padayatchi N, "Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study", J Antimicrob Chemother, 69, pp.3103~3107 (2014)
66. Tang S, "Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China", Clin Infect Dis, 60, pp.1361~1367 (2015)
67. Aung KJ, "Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients", Int J Tuberc Lung Dis, 18, pp.1180~1187 (2014)
68. Yew WW, "Fluoroquinolone resistance in Mycobacterium tuberculosis: what have we learnt?", Int J Tuberc Lung Dis, 18, pp.1~2 (2014)
69. Nunn AJ, "Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial", Trials, 15, pp.353~ (2014)
70. Dooley KE, "World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?", J Infect Dis, 207, pp.1352~1358 (2013)
71. Cox H, "Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis", Int J Tuberc Lung Dis, 16, pp.447~454 (2012)
72. Sotgiu G, "Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis", Eur Respir J, 40, pp.1430~1442 (2012)
73. Koh WJ, "Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients", J Antimicrob Chemother, 67, pp.1503~1507 (2012)
74. Lee M, "Linezolid for treatment of chronic extensively drug-resistant tuberculosis", N Engl J Med, 367, pp.1508~1518 (2012)
75. Chang KC, "Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?", Antimicrob Agents Chemother, 57, pp.3445~3449 (2013)
76. Chang KC, "WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis", Antimicrob Agents Chemother, 57, pp.4097~4104 (2013)
77. Dey T, "Outcomes of clofazimine for the treatment of drug-resistant tuberculosis : a systematic review and meta-analysis", J Antimicrob Chemother, 68, pp.284~293 (2013)
78. Gopal M, "Systematic review of clofazimine for the treatment of drug-resistant tuberculosis", Int J Tuberc Lung Dis, 17, pp.1001~1007 (2013)
79. Payen MC, "Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis", Int J Tuberc Lung Dis, 16, pp.558~560 (2012)
80. De Lorenzo S, "Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-", XDR-TB, 2013, pp.41, 1386~1392
81. Diacon AH, "The diarylquinoline TMC207 for multidrug-resistant tuberculosis", N Engl J Med, 360, pp.2397~2405 (2009)
82. Diacon AH, "Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance", Antimicrob Agents Chemother, 56, pp.3271~3276 (2012)
83. Diacon AH, "Multidrug-resistant tuberculosis and culture conversion with bedaquiline", N Engl J Med, 371, pp.723~732 (2014)
84. Guglielmetti L, "Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis:interim analysis of a French cohort", Clin Infect Dis, 60, pp.188~194 (2015)
85. Gler MT, "Delamanid for multidrug-resistant pulmonary tuberculosis", N Engl J Med, 366, pp.2151~2160 (2012)
86. Skripconoka V, "Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis", Eur Respir J, 41, pp.1393~1400 (2013)
87. Wells CD, "Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid", Eur Respir J, 45, pp.1498~1501 (2015)
88. Isaakidis P, "Adverse events among HIV", MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India, 2012, pp.7, e40781~
89. Daskapan A, "The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection", Eur Respir J, 45, pp.569~571 (2015)
90. Sotgiu G, "Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment", Int J Infect Dis, 32, pp.101~104 (2015)
91. Horsburgh CR Jr, "Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis", Int J Tuberc Lung Dis, 17, pp.146~152 (2013)
92. Huang TS, "In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years", Antimicrob Agents Chemother, 52, pp.2226~2227 (2008)
93. Zhang Z, "Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China", Int J Antimicrob Agents, 43, pp.231~235 (2014)
94. Hartkoorn RC, "Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis", Antimicrob Agents Chemother, 58, pp.2979~2981 (2014)
95. Andries K, "Acquired resistance of Mycobacterium tuberculosis to bedaquiline", PLoS One, 9, pp.e102135~ (2014)
96. Somoskovi A, "A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment", Eur Respir J, 45, pp.554~557 (2015)
97. Gupta S, "Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis", Antimicrob Agents Chemother, 58, pp.574~576 (2014)
98. Gupta S, "Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model", Antimicrob Agents Chemother, 59, pp.673~676 (2015)
99. Dharmadhikari AS, "Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis", Antimicrob Agents Chemother, 57, pp.2613~2619 (2013)
100. Park JH, "Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation", Int J Pharm, 441(1-2), pp.562~569 (2013)
101. Verma RK, "Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice", Antimicrob Agents Chemother, 57, pp.1050~1052 (2013)
102. Sung JC, "Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation", Antimicrob Agents Chemother, 53, pp.1338~1343 (2009)

관련 논문AI추천